CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-14
DOI
10.1007/s00262-020-02838-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
- (2019) Benedetto Sacchetti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Frontline Science: Late CD27 stimulation promotes IL‐7Rα transcriptional re‐expression and memory T cell qualities in effector CD8 + T cells
- (2019) Han Dong et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
- (2019) Zhitao Ying et al. Molecular Therapy-Oncolytics
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
- (2018) Li-Na Zhang et al. Journal of Hematology & Oncology
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
- (2018) Alvaro Teijeira et al. Cancer Immunology Research
- Programming CAR-T cells to kill cancer
- (2018) Louai Labanieh et al. Nature Biomedical Engineering
- High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma
- (2018) Genxiong Tang et al. PATHOLOGY RESEARCH AND PRACTICE
- Targeting Costimulatory Pathways in Systemic Sclerosis
- (2018) Gonçalo Boleto et al. Frontiers in Immunology
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
- (2016) Bishoy Faltas et al. Clinical Genitourinary Cancer
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Adoptive cellular therapy: A race to the finish line
- (2015) Carl H. June et al. Science Translational Medicine
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- CD28z CARs and Armored CARs
- (2014) Hollie J. Pegram et al. CANCER JOURNAL
- Late Signals from CD27 Prevent Fas-Dependent Apoptosis of Primary CD8+ T Cells
- (2014) D. V. Dolfi et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trop-2 Promotes Prostate Cancer Metastasis By Modulating 1 Integrin Functions
- (2013) M. Trerotola et al. CANCER RESEARCH
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
- TROP2 Expressed in the Trunk of the Ureteric Duct Regulates Branching Morphogenesis during Kidney Development
- (2011) Yuko Tsukahara et al. PLoS One
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
- (2010) Eliana Bignotti et al. EUROPEAN JOURNAL OF CANCER
- The Pim Kinase Pathway Contributes to Survival Signaling in Primed CD8+ T Cells upon CD27 Costimulation
- (2010) V. Peperzak et al. JOURNAL OF IMMUNOLOGY
- Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells
- (2010) Drew J. Roberts et al. JOURNAL OF IMMUNOTHERAPY
- Trop2: A possible therapeutic target for late stage epithelial carcinomas
- (2009) Rafael Cubas et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver
- (2009) M. Okabe et al. DEVELOPMENT
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
- (2008) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started